Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies, with a focus on relapsed/refractory AL amyloidosis. Its lead program, NXC-201, is a sterically optimized BCMA-targeted CAR-T designed to attack the plasma-cell clones that drive the disease. The company targets patients with serious, often hard-to-treat protein-misfolding and related conditions rather than broad commercial oncology markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -6.6 | — |
| Q3 2025 | 0 | — | -7.6 | — |
| Q4 2025 | 0 | — | -10.7 | — |
| Q1 2026 | 0 | — | -10.1 | — |
| Q2 2026 | 0 | — | -11.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Alpha and Omega Semiconductor Limited (AOSL), Achieve Life Sciences, Inc. (ACHV), Starling Oncology, Inc. (STLN), Thornburg Income Builder Opportunities Trust (TBLD), Legacy Housing Corporation (LEGH), OneSpan Inc. (OSPN)